相关实验视频

Updated: May 22, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

在患有高氏病1型的儿童中,使用Eliglustat基质还原疗法

Noor Ul Ain¹, Armaan Saith¹, Audrey Ruan¹

¹Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.

Frontiers in pediatrics

|March 14, 2025

概括

伊利格斯拉特基质减小疗法 (SRT) 有效治疗小儿高氏病1型 (GD1),在疾病标志物和生活质量方面持续改善,具有有利的安全性.

科学领域:

生物化学生物化学
遗传学遗传学是一个
儿科医学儿科医学

背景情况:

氏病 (Gaucher disease,简称GD) 是一种罕见的溶酶体储存障碍,儿童患者的治疗选择有限.
使用eliglustat的口服基质减小疗法 (SRT) 是一种潜在的替代方案,特别是对于那些面临酶替代疗法 (ERT) 挑战的人来说.

研究的目的:

评估 eliglustat SRT 的安全性和有效性,用于1型高氏病 (GD1) 的儿科患者.
评估 eliglustat 作为初始疗法和从静脉注射ERT转换.

主要方法:

从2017年到2024年,在耶鲁大学国家高希氏病治疗中心进行了一系列潜在的病例研究.
14名患有ERT障碍的儿科GD1患者接受了基于CYP2D6代谢器状态的药基因组学剂量的eliglustat SRT.
结果包括使用PROMIS问卷调查的安全性,有效性,逆转疾病活动指标,以及生活质量的变化.

主要成果:

伊利格斯拉特在平均年龄为12.5岁时开始使用,平均使用时间为3.6年.
所有患者都表现出葡萄糖素 (GlcSph) 水平 (p=0.005) 和其他疾病指标的持续降低.
副作用是最小的 (21%的过渡性胃食道逆流),心电图正常,生长和发育适当.

结论:

埃利格斯拉特SRT在儿科GD1患者中显示出显著的临床益处,包括降低GlcSph水平和改善生活质量.
该疗法在儿童中表现出良好的安全性,与成人数据相比.
埃利格斯拉特为儿科GD1患者提供了一种有前途且有效的ERT替代方案.

关键词:

氏病 (GD) 是一种疾病.符合资格的企业溶酶体储存疾病 (LSD) 是一种疾病.精准医学是一门精准医学.基底降解疗法 (SRT) 是一种降解疗法.

更多相关视频

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

相关概念视频

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...